GMI makes almost $13m from selling access to Irish data banks
The genetic data harvesting company posted the results as calls were made for the Irish government to appoint a genomics medicine guru
Genetic data harvesting company Genomics Medicine Ireland (GMI) has made nearly $13 million from selling access to its Irish genetic data banks since it was founded, according to its most recently filed accounts.
It comes as experts attending a genomic medicine conference last week made several calls for the Irish state to urgently appoint a genomics medicine guru to better coordinate the gathering of the highly sensitive data, which can provide an in-depth genetic blueprint of...
Subscribe from just €1 for the first month!
What's Included
With any subscription you will have access to
-
Unlimited multi-device access to our iPad, iPhone and Android Apps
-
Unlimited access to our eReader library
-
Exclusive daily insight and opinion seven days a week
-
Create alerts to never miss a subject that matters to you
-
Get access to exclusive offers for subscribers on gifts and experiences
-
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Related Stories
Comment: Our reserves were not built to survive long Covid
The Asthma Society of Ireland wants to end deaths from the condition by 2030, but the prolonged pandemic has heaped pressure on its services
Design for Life: My father refuses to get the Covid-19 vaccine
Psychotherapist Siobhán Murray advises a reader on how to talk to her recently widowed father about loss, loneliness and his fear of taking a Covid-19 vaccine
Susan O’Keeffe: We must put women’s healthcare out of reach of the Church for good
Despite the progress and promises made in recent years, we risk going backwards if the state allows the Sisters of Charity have any part in the new National Maternity Hospital
Covid-19: India’s crisis brings vaccine access inequality into sharp focus
Advocates for global access to coronavirus jabs are calling for a more radical approach to their rollout by waiving intellectual property rights to the vaccines
